Advanced glycation endproducts (AGEs) as metabolic by-products that mediate neurodegeneration.
Description: PROJECT NARRATIVE Advanced Glycation End-products (AGEs) are by-products of various metabolic reactions especially glycolysis, that are known to accumulate with age enhancing the risk of diabetic pathologies and Alzheimer’s disease (AD). We will use Caenorhabditis elegans to dissect the conserved metabolic pathways that influence the production and detoxification of AGEs and how they modulate toxicity in models of Alzheimer disease. This work will identify therapeutic targets that influence neurodegeneration by mitigating the influence of AGEs during aging and in Alzheimer disease models.
Funder: National Institute on Aging
Funding type: research
Funder scheme: R01
Start date: 2019-09-15
End date: 2025-05-31
Investigator: PANKAJ KAPAHI
Institution: BUCK INSTITUTE FOR RESEARCH ON AGING
Subfield: Clinical Biochemistry
Domain: Life Sciences
Funded outputs count: 20
Funder award ID: R01AG061165
OpenAlex ID: G1532684384